🟢 Edesa Biotech is trading 0% up in pre-market

Edesa Biotech is trading at $2.57, 0% up in pre-market, unchanged from its October 16 close; no new company-specific announcement was identified for October 19.

• The latest company release, dated October 15, announced FDA clearance to expand its Phase 2 vitiligo study to U.S. sites.
• That earlier update does not establish a reason for the unchanged price. Supplied sector context reports biotech weakness, but Edesa Biotech is not moving in the same direction.